Adjunct professor, Department of Health Policy & Management, George Washington University

Public health physician, expert in pharmaceutical policy, former chief medical officer at TGA, former director of pharmaceutical policy in Australian DoH, principal negotiator of pharma provisions of AUS FTA

Experience

  • –present
    Adjunct Professor of Health Policy, George Washington University

Education

  •  
    ANU, BSc
  • 2001 
    University of Newcastle, MMedSc
  • 1996 
    University of Newcastle, BMed

Publications

  • 2015
    Pharma’s next frontier? New Threats to Public Health in the Regional Comprehensive Economic Partnership Agreement. , Aust NZ J Public Health
  • 2015
    Value-Based Purchasing and Disinvestment Strategies for Pharmaceuticals: An International Review. , Pharmacoeconomics
  • 2015
    Impact d’un “Qualifiant Biologique“ sur le droit de la Dénomination Commune Internationale des biomolecules., Rev Gen Dr Med
  • 2015
    Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans Pacific Partnership Agreement. , Med J Aust
  • 2014
    Transferability of results of cost utility analyses for biologicals for inflammatory conditions in Central and Eastern European countries. , Eur J Health Econ
  • 2014
    Faecal microbiota transplantation: A sui generis biological drug, not a tissue. , Ann Pharm France
  • 2014
    Substitution des biomédicaments: Prospective d’impact compétitif en droit comparé franco-américain. , Techniques Hospitalières
  • 2014
    Costs of New Treatments for Hepatitis C Infection , JAMA
  • 2014
    Revolution then evolution: The advance of health economic evaluation in Australia., Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
  • 2013
    Australia’s ‘Fourth Hurdle’ drug review comparing costs and benefits holds lessons for the United States., Health Affairs
  • 2013
    Applying rapid ‘de facto’ HTA in resource-limited settings: Experience from Romania., Health Policy
  • 2013
    Likely impact of the Trans Pacific Partnership Agreement on access to affordable medicines and health equity in New Zealand. , Health Policy
  • 2013
    Biosimilars and the European Experience: Implications for the United States. , Health Affairs
  • 2013
    Increased risk of intussusception associated with rotavirus vaccines in Australia’s national immunization program. , Clin Inf Dis
  • 2013
    The high price of “free” trade: US free trade agreements and access to medicines., J Law Med Ethics
  • 2012
    Persistence in health behaviors among Medicare beneficiaries. , Open Journal of Preventive Medicine
  • 2012
    Impact of Medication Adherence on Medicare Expenditure among Beneficiaries with Heart Failure, Am J Man Care
  • 2012
    Willingness to Pay for Cancer Therapy. , Health Affairs
  • 2012
    Medication information for patients with limited English proficiency: Lessons from the European Union. , J Law Med Ethics
  • 2012
    Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes, Value in Health
  • 2011
    . Does Medication Adherence Lower Medicare Spending among Medicare Beneficiaries with Diabetes? , Health Services Research
  • 2010
    Child influenza vaccination: Panvax febrile reactions not a predictor. , BMJ
  • 2010
    Benefits and risks of trivalent 2010 seasonal influenza vaccine in Australian children, Eurosurveillance
  • 2009
    Comparative Effectiveness Research and Evidence- Based Health Policy: Experience from Four Countries. , Milbank Quarterly
  • 2009
    PBS Co-payments and Safety Nets. , Aust Health Review
  • 2009
    Medicines and Markets: the USA and Australia. , Australian Prescriber
  • 2008
    Toward a Definition of Pharmaceutical Innovation. , Open Medicine
  • 2007
    Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and USA. , Value in Health
  • 2007
    What is fair? Choice, Fairness, and Transparency in Access to Prescription Medicines in the US and Australia. , J Law Med Ethics
  • 2007
    Towards a rational, value-based drug benefit for Medicare. , Health Affairs
  • 2007
    International Price Comparisons for Novel and Follow-on Drugs: A Response. , Value in Health
  • 2003
    Use of pharmacoeconomics in prescribing research. Part 3: Cost- effectiveness analysis. , J Clin Pharm Ther
  • 2003
    Use of pharmacoeconomics in prescribing research. Part 5: Modeling – beyond clinical trials. , J Clin Pharm Ther
  • 2002
    The Pharmaceutical Benefits Scheme: Economic evaluation works ... but is not a panacea. , Australian Prescriber
  • 2002
    Differential pricing of drugs: A role for cost effectiveness analysis? , Lancet
  • 1999
    Pharmacoeconomics and policy decisions: The Australian health care system., Clin Ther
  • 1997
    A randomised controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits., Am J Sports Med
  • 1996
    Drug-induced delirium: Incidence, management and prevention. , Drug Safety

Professional Memberships

  • Fellow of the Faculty of Public Health Medicine, Royal Australasian College of Physicians

Honours

20006-07 Harkness Fellow in Health Policy

  • Washington , DC
  • Article Feed
  • rlopert@gwu.edu
  • Joined